

**THE NASDAQ STOCK MARKET LLC  
LETTER OF ACCEPTANCE, WAIVER AND CONSENT  
NO. 2015045755502**

TO: The Nasdaq Stock Market LLC  
c/o Department of Enforcement  
Financial Industry Regulatory Authority (“FINRA”)

RE: John Grifonetti, Respondent  
Former General Securities Principal  
CRD No. 3040205

Pursuant to Rule 9216 of The Nasdaq Stock Market LLC (“Nasdaq”) Code of Procedure, I, Respondent John Grifonetti (“Grifonetti” or “Respondent”) submit this Letter of Acceptance, Waiver and Consent (“AWC”) for the purpose of proposing a settlement of the alleged rule violations described below. This AWC is submitted on the condition that, if accepted, Nasdaq will not bring any future actions against Respondent alleging violations based on the same factual findings described herein.

**I.**

**ACCEPTANCE AND CONSENT**

A. Respondent hereby accepts and consents, without admitting or denying the findings, and solely for the purposes of this proceeding and any other proceeding brought by or on behalf of Nasdaq, or to which Nasdaq is a party, prior to a hearing and without an adjudication of any issue of law or fact, to the entry of the following findings by Nasdaq:

**BACKGROUND**

Grifonetti entered the securities industry in 1998. In July 2011, Grifonetti and several business partners founded broker-dealer Bayes Capital LLC (CRD No. 159644) (“Bayes” or the “firm”). Bayes became registered with Nasdaq on February 9, 2015. Grifonetti registered with Nasdaq as, *inter alia*, a General Securities Principal (“GP”) at Bayes on February 9, 2015. Bayes filed a Uniform Request for Broker-Dealer Withdrawal (Form BDW) on May 4, 2018, and its registration with Nasdaq was terminated on June 4, 2018. Grifonetti’s registration with Nasdaq was also terminated on June 4, 2018. On July 2, 2018, the firm filed a Form U5 on behalf of Grifonetti.

Grifonetti is not currently employed in the securities industry and is not registered or associated with any Nasdaq member firm. Although he is no longer associated with a Nasdaq member firm, he remains subject to Nasdaq’s jurisdiction pursuant to Nasdaq Rule 1031(f), which was in effect when Grifonetti’s registration with Nasdaq was

terminated.<sup>1</sup> He remains subject to Nasdaq's jurisdiction until June 3, 2020.

### **RELEVANT DISCIPLINARY HISTORY**

Grifonetti does not have any disciplinary history with the U.S. Securities and Exchange Commission ("SEC"), any state securities regulators, Nasdaq, or any other self-regulatory organization ("SRO").

### **OVERVIEW**

Between November 2014 and July 2, 2018, Bayes was a small firm that had approximately five employees. Grifonetti, who served as the firm's Chief Executive Officer ("CEO") and Chief Compliance Officer ("CCO") from November 2014 through December 2016, and a business partner (the "Business Partner"), who succeeded Grifonetti as the firm's CEO and CCO, were two primary decision-makers at the firm. At all relevant times, Grifonetti delegated to his Business Partner responsibility for establishing and maintaining the firm's supervisory system in relation to achieving compliance with rules prohibiting manipulative trading and compliance with Rule 15c3-5 of Section 15(c)(3) of the Securities Exchange Act of 1934 (the "Market Access Rule"). Grifonetti, however, failed to take reasonable steps to ensure that his Business Partner was properly qualified to discharge these functions and failed to implement a reasonable system of follow-up and review to ensure that his Business Partner was reasonably discharging these functions.

The firm's business was initially limited to agency trading on behalf of institutional customers. In November 2014, Grifonetti and his Business Partner expanded the firm's business to include providing direct market access for an unaffiliated broker dealer ("BD1"). BD1's customers included unregistered foreign day trading entities. One of BD1's customers was an unregistered foreign-day trading entity and non-FINRA/SRO member, Customer X, which was under common ownership and control with the firm's third-party, market access control vendor (the "Market Access Control Vendor"). Although this expanded business significantly changed Bayes's business activities and trading volume, the firm failed to reasonably enhance the firm's supervisory system, including its written supervisory procedures ("WSPs"), to achieve compliance with applicable federal securities laws and regulations and Nasdaq rules prohibiting manipulative trading. The firm also failed to establish and implement a system of risk management controls and WSPs reasonably designed to manage the financial, regulatory, and other risks of this business. As a result of these failures, Customer X, first through BD1, then through another introducing broker ("BD2"), and later as a direct customer of the firm, engaged in various forms of potentially manipulative trading, including, but not

---

<sup>1</sup> Nasdaq subsequently adopted a new jurisdiction rule. The new jurisdiction rule only applies, however, to "members or associated persons who terminate with [Nasdaq] on or after October 15, 2018." Securities Exchange Act Release No.34-84355 (Oct. 3, 2018), 83 FR 51015, 51017 (Oct. 10, 2018).

limited to, layering<sup>2</sup> and spoofing.<sup>3</sup>

Accordingly, during the period from February 9, 2015 through June 4, 2018 (the “Relevant Period”), Grifonetti violated Nasdaq Rules 3010 and 2010A.

## **FACTS AND VIOLATIVE CONDUCT**

### *Applicable Rules*

1. Nasdaq Rule 3010(a) requires members to establish and maintain a supervisory system, as well as to establish, maintain and enforce WSPs, reasonably designed to achieve compliance with applicable securities laws and regulations, and with applicable Nasdaq rules.
2. Pursuant to NASD Rule 3010(a)(6), which members were required to comply with during the Relevant Period pursuant to Nasdaq Rule 3010(a), members were required to use “[r]easonable efforts to determine that all supervisory personnel are qualified by virtue of experience or training to carry out their assigned responsibilities.”
3. Nasdaq Rule 2010A requires an associated person to observe high standards of commercial honor and just and equitable principles of trade in the conduct of his or her business. A violation of Nasdaq Rule 3010 also constitutes a violation of Nasdaq Rule 2010A.
4. In 2010, the SEC adopted the Market Access Rule to require that broker-dealers with market access appropriately control the risks associated with market access, so as not to jeopardize their own financial condition, that of other market participants, the integrity of trading on the securities markets, and the stability of the financial system. The Market Access Rule establishes specific requirements for broker-dealers providing market access, including that such firms establish, document, and maintain a system of risk management controls and supervisory procedures reasonably designed to manage the financial, regulatory, or other risks of its business. The Market Access Rule further specifies the required elements for risk management controls and supervisory procedures and mandates that the controls and procedures be

---

<sup>2</sup> Layering is a form of market manipulation that typically includes placement of multiple limit orders on one side of the market at various price levels at or away from the National Best Bid and Offer (“NBBO”) that are intended to create the appearance of a change in the levels of supply and demand. In some instances, layering involves placing multiple limit orders at the same or varying prices across multiple exchanges or other trading venues. An order is then executed on the opposite side of the market and most, if not all, of the multiple limit orders are immediately cancelled. The purpose of the multiple limit orders that are subsequently cancelled is to induce, or trick, other market participants to enter orders due to the appearance of interest created by the orders such that the trader is able to receive a more favorable execution on the opposite side of the market.

<sup>3</sup> Similar to layering, spoofing involves placement of non-bona fide orders, generally inside the existing NBBO, with the intention of briefly triggering some type of response from another market participant, followed by cancellation of the non-bona fide order, and the entry of an order on the other side of the market.

under the direct and exclusive control of the broker-dealer.

5. In the Adopting Release of the Market Access Rule, as well as subsequent guidance, the SEC explained that the Market Access Rule requires market access providers to perform “appropriate due diligence” on their market access control vendors. The due diligence may include, *inter alia*, a review of publicly available information about the ownership and material business relationships of market access control vendors and market access customers, follow up on any information that may indicate a lack of independence between market access control vendors and market access customers, and requests to market access control vendors and market access customers to certify their independence from each other.<sup>4</sup>

*Grifonetti and his Business Partner Launched Bayes’s  
Direct Market Access Business Without Conducting Appropriate  
Due Diligence on the Market Access Control Vendor, BD1 and Customer X*

6. Between November 2014 and July 2, 2018, Bayes was a small firm that provided direct market access to U.S. securities markets for several of its customers. Grifonetti was both an owner of the firm and its CEO and CCO until December 2016. After stepping down as CEO and CCO, he remained an owner and a GP at the firm. Grifonetti and his Business Partner, who was the firm’s Head of Trading prior to becoming the firm’s CEO and CCO in December 2016, were two primary decision-makers at the firm in all aspects of the firm’s business until December 2016.
7. Prior to November 2014, the firm conducted an agency-only business for a handful of institutional customers. The firm did not provide direct market access, and was looking into new business lines to generate additional revenue.
8. In mid-2014, the Market Access Control Vendor presented the firm with a potentially lucrative package deal: Bayes would receive order flow routed from BD1 and its customers, including Customer X, so long as it used the Market Access Control Vendor’s proprietary risk management system and controls to manage the firm’s direct market access business. The package deal proposed by the Market Access Control Vendor should have raised concerns for Grifonetti and his Business Partner about potential conflicts of interest between the Market Access Control Vendor and Customer X per the guidance set forth in the Adopting Release of the Market Access Rule.
9. For instance, prior to Bayes providing direct market access to BD1 and Customer X, Grifonetti and his Business Partner received emails and other documents showing that the Market Access Control Vendor and Customer X were under common ownership and control. Neither Grifonetti nor his Business Partner, however, took reasonable

---

<sup>4</sup> E.g., SEC, *Risk Management Controls for Brokers or Dealers with Market Access*, Release No. 34-63241 (Nov. 3, 2010); see also SEC Division of Trading and Markets, *Responses to Frequently Asked Questions Concerning Risk Management Controls for Brokers or Dealers with Market Access* (Apr. 15, 2014), available at <https://www.sec.gov/divisions/marketreg/faq-15c-5-risk-management-controls-bd.htm>.

steps to mitigate the potential conflict of interest posed by allowing Customer X to route order flow through the Market Access Control Vendor's proprietary pre-trade risk controls.

10. In November 2014, without conducting appropriate due diligence with respect to the potential conflict of interest between the Market Access Control Vendor and Customer X, nor collecting any due diligence documentation relating to BD1, Grifonetti and his Business Partner launched Bayes's direct market access business pursuant to the package deal proposed by the Market Access Control Vendor. Thus, Bayes began providing direct market access to day-trading groups that routed orders through BD1, including Customer X. The firm agreed to carve out an exception in the Routing Services Agreement with BD1 pursuant to which the firm would not charge any fees for routing Customer X's orders.
11. BD1, and in particular Customer X, immediately became the primary source of order flow and revenue to Bayes. In 2015 and 2016, order flow from BD1 generated over 92 percent of the firm's total commissions, with order flow from Customer X alone constituting approximately 60 percent of that order flow. The trading volume resulted in discounts and preferential pricing at various exchanges, which made this order flow more lucrative to the firm. Further, the revenues earned by the firm routing order flow from BD1, including Customer X, dwarfed revenues it earned from other customers.

*Grifonetti Failed to Establish and Maintain  
a Reasonably Designed Supervisory System and WSPs  
to Manage and Supervise the Firm's Direct Market Access Business*

12. Pursuant to Bayes's WSPs dated December 2014, which Grifonetti approved, he was responsible for establishing and maintaining the firm's supervisory system and policies and procedures for all areas of the firm, including market access. Until he stepped down as CEO and CCO in December 2016, however, Grifonetti delegated this responsibility to his Business Partner.
13. Although the delegation of supervisory responsibility is not improper, there has to be a reasonable system in place for review of the delegated responsibility. First, NASD Rule 3010(a)(6), which was applicable to members pursuant to Nasdaq Rule 3010(a), required the use of reasonable efforts to determine that all supervisory personnel are qualified, either by virtue of experience or training, to carry out their assigned responsibilities. This "is an ongoing obligation."<sup>5</sup> Second, supervisors must take reasonable action to ensure delegated functions are properly executed. "[I]t is 'not sufficient for the person with overarching supervisory responsibility to delegate supervisory responsibility to a subordinate, even a capable one, and then simply wash his hands of the matter until a problem is brought to his attention . . . . Implicit is the

---

<sup>5</sup> See NASD Notice to Members 99-45, at 298 (June 1999).

additional duty to follow-up and review that delegated authority to ensure that it is being properly exercised.”<sup>6</sup>

14. Grifonetti had no experience in establishing or managing a direct market access business. He wholly relied on his Business Partner and a compliance consultant hired by the firm to consult on such issues to establish the firm’s risk controls under the Market Access Rule, as well as to supervise and conduct trade surveillance of Bayes’s market access business and customer trading activity. But Grifonetti failed to use reasonable efforts to ensure that his Business Partner was properly qualified to fulfill his supervisory duties. And, in fact, his Business Partner lacked experience and training in supervising direct market access order flow and in setting reasonable pre-trade risk controls for such order flow.
15. Grifonetti also failed to implement a system of follow up and review. In addition, he failed to take reasonable steps to determine if his Business Partner was reasonably exercising this delegated authority. As such, Grifonetti’s delegation of supervisory responsibility was not reasonable.
16. Without a reasonable delegation, Grifonetti was required to take reasonable steps to achieve compliance with applicable Nasdaq rules and federal securities laws and regulations, by establishing and maintaining the firm’s supervisory system, policies and procedures with respect to the firm’s direct market access business, including the firm’s WSPs; to reasonably investigate red flags of potential misconduct (including potentially manipulative trading); and to take reasonable action when such misconduct has occurred.
17. Before Grifonetti and his Business Partner launched the firm’s direct market access business, FINRA had issued public guidance regarding risks related to foreign day traders manipulating U.S. markets.<sup>7</sup>
18. In establishing the firm’s market access controls and throughout the Relevant Period, the Business Partner instead relied on guidance from the Market Access Control Vendor when setting its pre-trade controls to filter trading activity of direct market access customers, including Customer X. Further, the Market Access Control Vendor had the ability, without requiring input or approval from Bayes, to suspend or re-enable access at an account level through its platform. The Market Access Vendor also had the exclusive ability to make intraday adjustments to the financial management controls within its platform. Separately, the firm relied on guidance from BD1 with respect to setting the firm’s market access controls and limits for individual accounts, including specifically with respect to Customer X.
19. Further, Bayes’s supervisory system relied on (a) the Market Access Control Vendor’s pre-trade risk controls, (b) the firm’s ability to view order and trading

---

<sup>6</sup> *In re Pellegrino*, 2008 SEC LEXIS 2843, at \*47 (S.E.C. Dec. 19, 2008).

<sup>7</sup> See FINRA’s 2013 Priorities Letter (Jan. 11, 2013); see also FINRA’s 2014 Priorities Letter (Jan. 2, 2014).

activity in real time, and (c) the Business Partner's manual review of reports generated by the vendor of rejected orders as the firm's supervisory system with respect to potentially manipulative trading activity by direct market access customers. Between December 2014 and January 2016 alone, however, BD1 routed more than 305 million orders through Bayes.<sup>8</sup> During the same time period, there were more than 5.4 million rejected orders on a pre-trade basis from BD1, a substantial portion of which may have related to potential layering or spoofing activity from Customer X. Despite the massive volume of rejected orders, there is only one documented instance in which Bayes contacted BD1 in relation to a review of a rejection report.

20. Bayes failed to conduct post-trade reviews for potentially manipulative trading by direct market access customers until approximately May 2016, after FINRA alerted the firm of its obligation to do so. Thereafter, Bayes hired a compliance analyst to be responsible for implementing and conducting the firm's post-trade reviews. The analyst, however, had no relevant experience or background in trade surveillance.
21. In July 2016, Grifonetti approved updated WSPs. Until Grifonetti approved the July 2016 WSPs, the firm's WSPs did not address conflicts of interest with third-party vendors. The July 2016 WSPs were updated to include procedures requiring the firm to assure itself that a third-party provider of risk management controls is not an affiliate, and is otherwise independent of, any market access customer of the firm. Despite the new procedures, which Grifonetti approved, the firm continued to provide market access to Customer X using the Market Access Control Vendor's risk management controls.

*Grifonetti Failed to Reasonably Supervise Order Flow from BD1*

22. In September 2015, less than a year after launching its direct market access business, Bayes started to receive the first of many regulatory inquiries regarding the firm's market access controls, supervisory procedures, and surveillances to detect and prevent potentially manipulative trading activity by direct market access customers.
23. Then, in February 2016, BD1 was censured and fined in settled disciplinary proceedings brought by FINRA and multiple exchange SROs for, *inter alia*, BD1's failure to supervise direct market access customers for potential layering, spoofing, and other trading violations. The disciplinary proceedings against BD1 were public, yet Bayes failed to perform any additional scrutiny of BD1's customers' account activity routed through Bayes.
24. On February 29, 2016, FINRA notified Bayes, including Grifonetti, that it had determined that the firm's pre-trade risk management controls were not in compliance with the Market Access Rule, that the firm did not conduct reasonable post-trade analysis, and that the firm had failed to demonstrate direct and exclusive control of its

---

<sup>8</sup> In view of the volume of the order flow, neither real-time nor manual review of order and trading activity were reasonable here.

direct market access business.

25. Further, Grifonetti received information that should have put him on notice of the common ownership and controls of the Market Access Control Vendor and Customer X. He nonetheless failed to take reasonable steps to ensure that the Market Access Control Vendor was independent from Customer X and failed to perform reasonable follow-up and review to ensure that his Business Partner was reasonably discharging this obligation.
26. Despite the multiple red flags regarding potentially manipulative activity as described above, all of which Grifonetti knew or should have known related to potentially manipulative activity involving order flow routed through BD1, Bayes failed to perform reasonable supervisory oversight on order flow from BD1. As a result, the potentially manipulative activity continued. Grifonetti again failed to conduct reasonable follow up and review of his Business Partner to determine if he was reasonably discharging his delegated supervisory obligations in light of these potential red flags.

*Grifonetti Failed to Reasonably Supervise Order Flow from BD2*

27. In October 2016, Customer X moved its account from BD1 to BD2. Grifonetti and his Business Partner thereupon established a market access arrangement with BD2, and BD2 started sending order flow to Bayes, including from Customer X.
28. BD2 had previously been censured and fined in a settled disciplinary proceeding brought by an exchange SRO in February 2015 for, *inter alia*, failing to have reasonable supervisory procedures and controls in place designed to achieve compliance with rules against potentially manipulative trading practices by market access customers. The disciplinary proceeding against BD2 was also public, yet Bayes failed to perform any additional scrutiny of BD2's customers' account activity routed through Bayes.
29. Despite the disciplinary proceeding against BD2, which Grifonetti knew or should have known about, Grifonetti failed to take reasonable steps to determine if his Business Partner was performing appropriate due diligence or implementing reasonable supervisory oversight on order flow from BD2.

*Despite Red Flags, Bayes Agreed to Take on Customer X  
as a Direct Customer of Bayes*

30. In or about January 2017, BD2 requested that Bayes agree to have Customer X route its order flow directly to Bayes, rather than through BD2, because BD2 stated that it was concerned about risks relating to Customer X's order flow. Although Grifonetti stepped down as CEO of Bayes in December 2016, he remained a GP at the firm.
31. Despite concerns about potentially problematic order flow from Customer X and

knowledge of the common ownership of Customer X and the Market Access Control Vendor, the firm agreed to take on Customer X as a direct customer of the firm. As a result, Customer X continued to route potentially manipulative trades to U.S. trading markets through Bayes.

32. It was only in May 2017, after Grifonetti and others at Bayes attended a meeting with FINRA and several exchange SROs regarding Customer X's problematic order flow, when Bayes terminated its relationship with Customer X. Bayes nonetheless continued providing direct market access to other customers until the firm ceased to operate in July 2018.

33. Based on the foregoing, Grifonetti violated Nasdaq Rules 3010 and 2010A.

B. I also consent to the imposition of the following sanction:

A censure, a principal bar, a 12-month suspension in all capacities and a total fine of \$75,000, of which \$8,333.33 shall be paid to Nasdaq.<sup>9</sup>

I agree to pay the monetary sanction upon notice that this AWC has been accepted and that such payment is due and payable. I have submitted a Payment Information form with my billing contact information for payment of the fine imposed.

I specifically and voluntarily waive any right to claim that I am unable to pay, now or at any time hereafter, the monetary sanction imposed in this matter.

I understand that if I am barred or suspended from associating with any Nasdaq member, I become subject to a statutory disqualification as that term is defined in Section 3(a)(39) of the Securities Exchange Act of 1934, as amended. Accordingly, I may not be associated with any Nasdaq member in any capacity, including clerical or ministerial functions, during the period of the bar or suspension. *See* Nasdaq Rule 8310 and IM-8310-1.

I also understand that if I am barred or suspended from associating with any Nasdaq member in a principal capacity, I become subject to a statutory disqualification as that term is defined in Section 3(a)(39) of the Securities Exchange Act of 1934, as amended. Accordingly, I may not be associated with any Nasdaq member in a barred capacity, during the period of the bar or suspension. *See* Nasdaq Rule 8310 and IM-8310-1. Furthermore, because I am subject to a statutory disqualification during the bar, if I remain associated with a member firm in a non-barred capacity, an application to continue that association may be required.

---

<sup>9</sup> The remainder of the fine shall be paid to FINRA, Cboe BZX Exchange, Inc., Cboe BYX Exchange, Inc., Cboe EDGA Exchange, Inc., Cboe EDGX Exchange, Inc., Nasdaq BX, Inc. and Nasdaq PHLX LLC.

The sanctions imposed herein shall be effective on a date set by FINRA staff. Pursuant to IM-8310-3(e), a bar or expulsion shall become effective upon approval or acceptance of this AWC.

## II.

### WAIVER OF PROCEDURAL RIGHTS

I specifically and voluntarily waive the following rights granted under Nasdaq's Code of Procedure:

- A. To have a Formal Complaint issued specifying the allegations against me;
- B. To be notified of the Complaint and have the opportunity to answer the allegations in writing;
- C. To defend against the allegations in a disciplinary hearing before a hearing panel, to have a written record of the hearing made and to have a written decision issued; and
- D. To appeal any such decision to the Nasdaq Review Council and then to the SEC and a U.S. Court of Appeals.

Further, I specifically and voluntarily waive any right to claim bias or prejudice of the Chief Regulatory Officer, the Nasdaq Review Council, or any member of the Nasdaq Review Council, in connection with such person's or body's participation in discussions regarding the terms and conditions of this AWC, or other consideration of this AWC, including acceptance or rejection of this AWC.

I further specifically and voluntarily waive any right to claim that a person violated the *ex parte* prohibitions of Rule 9143 or the separation of functions prohibitions of Rule 9144, in connection with such person's or body's participation in discussions regarding the terms and conditions of this AWC, or other consideration of this AWC, including its acceptance or rejection.

## III.

### OTHER MATTERS


I understand that:

- A. Submission of this AWC is voluntary and will not resolve this matter unless and until it has been reviewed and accepted by FINRA's Department of Enforcement and the Nasdaq Review Council, the Review Subcommittee, or the Office of Disciplinary Affairs ("ODA"), pursuant to Nasdaq Rule 9216;
- B. If this AWC is not accepted, its submission will not be used as evidence to prove any of the allegations against me; and

- C. If accepted:
1. this AWC will become part of my permanent disciplinary record and may be considered in any future action brought by Nasdaq or any other regulator against me;
  2. Nasdaq may release this AWC or make a public announcement concerning this agreement and the subject matter thereof in accordance with Nasdaq Rule 8310 and IM-8310-3; and
  3. I may not take any action or make or permit to be made any public statement, including in regulatory filings or otherwise, denying, directly or indirectly, any finding in this AWC or create the impression that the AWC is without factual basis. I may not take any position in any proceeding brought by or on behalf of Nasdaq, or to which Nasdaq is a party, that is inconsistent with any part of this AWC. Nothing in this provision affects my right to take legal or factual positions in litigation or other legal proceedings in which Nasdaq is not a party.
- D. I may attach a Corrective Action Statement to this AWC that is a statement of demonstrable corrective steps taken to prevent future misconduct. I understand that I may not deny the charges or make any statement that is inconsistent with the AWC in this Statement. This Statement does not constitute factual or legal findings by Nasdaq, nor does it reflect the views of Nasdaq or its staff.

I certify that I have read and understand all the provisions of this AWC and have been given a full opportunity to ask questions about it; that I have agreed to the AWC's provisions voluntarily; and no offer, threat, inducement, or promise of any kind, other than the terms set forth herein and the prospect of avoiding the issuance of a Complaint, has been made to induce me to submit it.

5/26/20  
Date

  
John Grifonetti  
Respondent

Accepted by Nasdaq:

May 29, 2020  
Date

*Elyse D. Kovar*  
Elyse D. Kovar, Senior Counsel  
Robert A. Gomez, Principal Counsel  
FINRA Department of Enforcement

Signed on behalf of Nasdaq, by delegated  
authority from the Director of ODA

**PAYMENT INFORMATION**

For individuals, please enter the billing contact information below and the Exchange's Billing Department will contact you. *Otherwise, please leave the following information blank.*

Billing Contact Name: John Grifonetti

Billing Contact Address: 2 STOKES Farm Road Old Tappan NJ 07675

Billing Contact Email: JohnGrifonetti@gmail.com

Billing Contact Phone Number: 201-252-3554

Respectfully submitted,

5/20/20

Date

Respondent

John Grifonetti

By: [Signature]

Name: John Grifonetti

Title: \_\_\_\_\_